Search

Your search keyword '"Ida Kappel Buhl"' showing total 4 results
Start Over Author "Ida Kappel Buhl" Topic cancer research
4 results on '"Ida Kappel Buhl"'

1. Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study

Author

Hella Danoe, Thomas Jensen, Erik Jakobsen, Vesna Glavicic, Jurij Bogovic, Dorte Nielsen, Eva Balslev, Annie Rasmussen, Peter Buhl Jensen, AS Knoop, Bent Ejlertsen, Ida Kappel Buhl, Ulrik Lassen, Joergen Hansen, Ulla Hald Buhl, Sven Tyge Langkjer, Steen Knudsen, Anker Jon Hansen, Mogens Winkel Madsen, and Soeren Linnet

Subjects
0301 basic medicine, Drug, Oncology, Cancer Research, medicine.medical_specialty, business.industry, media_common.quotation_subject, Phases of clinical research, medicine.disease, Metastatic breast cancer, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, Liposomal Cisplatin, 030220 oncology & carcinogenesis, Internal medicine, medicine, Biomarker (medicine), skin and connective tissue diseases, business, media_common
Abstract

e13077Background: In an ongoing, open-label Phase 2 study liposomal cisplatin (LiPlaCis) was evaluated in metastatic breast cancer (mBC) patients selected by a cisplatin-specific mRNA-based drug re...

Published
2018
Full Text
View/download PDF

2. Prospective blinded evaluation predicting efficacy of adjuvant cisplatinum and vinorelbine by a multigene assay after radical surgery in non-small cell lung cancer

Author

Peter Buhl Jensen, Anker Jon Hansen, Eric Santoni-Rugiu, Jens Benn Soerensen, Ida Kappel Buhl, Thomas Jensen, Steen Knudsen, Jon Askaa, Ib Jarle Christensen, and Jesper Ravn

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, medicine.disease, Vinorelbine, respiratory tract diseases, Internal medicine, medicine, Drug response, Non small cell, Radical surgery, Lung cancer, business, Adjuvant, medicine.drug
Abstract

e20007Background: This study evaluated the predictive effect of a mRNA-based Drug Response Predictor DRP in the adjuvant setting of non-small cell lung cancer (NSCLC). We apply a mathematical metho...

Published
2016
Full Text
View/download PDF

3. Versatile multigene expression biomarker for predicting clinical platinum sensitivity in non-small cell lung cancer (NSCLC) and ovarian cancer (OC)

Author

Eric Santoni-Rugiu, Peter Buhl Jensen, Ida Kappel Buhl, Mogens Winkel Madsen, Jesper Ravn, Ib Jarle Christensen, Jens Benn Sørensen, Thomas Jensen, Nils Brünner, Jon Askaa, Anker Jon Hansen, Steen Knudsen, and Ulla Hald Buhl

Subjects
Cancer Research, endocrine system diseases, Platinum sensitivity, business.industry, non-small cell lung cancer (NSCLC), Bioinformatics, medicine.disease, female genital diseases and pregnancy complications, Multigene expression, Oncology, Cancer research, Medicine, Biomarker (medicine), business, Ovarian cancer
Abstract

e18502 Background: There are no established biomarkers for prediction of clinical platinum sensitivity. A new platinum response prediction method using multigene expression is reported. Methods: We...

Published
2015
Full Text
View/download PDF

4. Use of microRNA to identify stage IV breast cancer patients to be targeted with phospholipase A2 disrupted cisplatin carrying liposomes: An ongoing phase I trial

Author

Peter Buhl Jensen, Iben Kümler, Nils Brünner, Ulla Hald Buhl, Steen Knudsen, Peter Michael Vestlev, Anker Jon Hansen, Dorte Nielsen, Eva Balslev, Bent Ejlertsen, Ulrik Lassen, Anne Vibeke Lænkholm, Thomas Jensen, Ida Kappel Buhl, Morten Mau Soerensen, Pernille Braemer Hertel, Mogens Winkel Madsen, and Jon Askaa

Subjects
Cisplatin, Cancer Research, Liposome, biology, business.industry, Bioinformatics, medicine.disease, Phospholipase A2, Breast cancer, Oncology, microRNA, Toxicity, Cancer research, biology.protein, Medicine, skin and connective tissue diseases, Stage iv, business, medicine.drug
Abstract

TPS1139 Background: Cisplatin has shown activity in BRCA associated breast cancer patients but generally the use of cisplatin in breast cancer has been hampered by high toxicity and low response ra...

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results